OIG - Office of Inspector General
07/13/2026 | Press release | Archived content
Corporate Integrity Agreement with EyePoint, Inc.
Location Watertown, MA Estimated Completion July 2031 Settlement Amount $4,678,981
AGREEMENT PRESS RELEASE
EyePoint Pharmaceuticals to Pay $4.6 Million to Resolve False Claims Act Allegations
July 20, 2026Published by the United States Department of Justice | View article on www.justice.gov
Published by the United States Department of Justice | View article on www.justice.gov
Eyepoint Pharmaceuticals, Inc., (EyePoint) headquartered in Massachusetts, has agreed to pay the United States $ 4,657,463.18 to resolve allegations that it violated the False Claims Act by paying kickbacks to certain Ambulatory Service Centers (ASCs) to induce those ASCs to purchase and dispense DEXYCU, an injectable drug approved for the treatment of ocular inflammation following cataract surgery, between January 1, 2019 and March 1, 2023.
OIG - Office of Inspector General published this content on July 13, 2026, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT), unedited and unaltered, on August 05, 2026 at 14:25 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]